Weekly Peptide Brief, Oral GLP-1s expand, FDA sharpens supplement oversight, and a BPC-157 reality check
Oral obesity drugs are widening access, FDA is signaling bigger changes for supplement compliance, and this week’s peptide and ingredient picks focus on what is real, what is hype, and what operators should actually do.